Prostatic Neoplasms Clinical Trial
| Verified date | June 2012 |
| Source | Astellas Pharma Inc |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | United States: Food and Drug Administration |
| Study type | Interventional |
The purpose of this study is to determine if patients who take YM598 in addition to mitoxantrone and prednisone (standard therapy) experience improvement in the pain associated with prostate cancer metastases in the bone.
| Status | Terminated |
| Enrollment | 0 |
| Est. completion date | June 2004 |
| Est. primary completion date | |
| Accepts healthy volunteers | No |
| Gender | Male |
| Age group | 18 Years and older |
| Eligibility |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| Australia | Department of Medical Oncology, The Canberra Hospital | Canberra | |
| Australia | Department of Medical Oncology, Concord Hospital Medical Centre | Concord | |
| Australia | Division of Oncology Ward, Royal Brisbane Hospital | Herston | |
| Australia | Department of Clinical Oncology, Royal North Shore Hospital | St Leonards | |
| Australia | Cancer Care Centre, St. George Hospital | Sydney | |
| Australia | Department of Medical Oncology, Newcastle Mater Hospital | Waratah | |
| Australia | Southern Medical Day Care Centre | Wollongong | |
| Australia | Queen Elizabeth Hospital, Clinical Hematology & Oncology | Woodville | |
| Belgium | Cliniques Universitaires St-Luc, Service d'Urologie | Bruxelles | |
| Belgium | Centre Hospitalier Notre Dame et Reine Fabiola, Service d'oncologie | Charleroi | |
| France | Centre Paul Papin | Angers | |
| France | Service d'Urologie, Hôpital Henri Mondor | Creteil | |
| France | Pavillon V, Service d'Urologie et de transplatation, Hôpital Edouard Herriot | Lyon | |
| France | Service d' Urologie CHU, Hopital Bichat | Paris | |
| Germany | Krankenhause am Urban, Urologie Dieffenfachstr | Berlin | |
| Germany | Dept Urology University of Essen | Essen | |
| Germany | Urologische Klinik der MHH | Hannover | |
| Germany | Klinikum Mannheim Urology | Mannheim | |
| Ireland | Mater Misericordiae Hospital | Dublin | |
| Netherlands | Universitair Medisch Centrum Utrecht, Dienst Medische Oncologie | Utrecht | |
| Poland | Kilinika Chemioterapii, Centrum Onkologii Instytut im M sklodowskiej Curie | Krakow | |
| Poland | Oddzial Chemioterapii | Krakow | |
| Poland | Klinika Chemioterapii AM | Lodz | |
| Poland | Samodzielny Publiczny Zaklad Opieki zdrowotnej, Wojewodzki Osrodek Onkologii | Opole | |
| Poland | Szpital Wojewodzki im Sw Lukasza SP ZOZ Tarnow | Tarnow | |
| Poland | Szpital CSK WAMl, Klinika Okologii | Warsaw | |
| Poland | Klinika Nowotworow Ukladu | Warszawa | |
| Spain | Hospital Clinic i Provincial, Servicio de Oncologia | Barcelona | |
| Spain | Hospital General Vall d'Hebron, Servicio de Oncología | Barcelona | |
| Spain | Hospital Universitario de Getafe, Servicio de Urologia, Crta | Getafe (Madrid) | |
| Spain | Hospital Universitario Príncipe de Asturias, Servicio de Urología | Madrid | |
| Spain | Instituto Valenciano de Oncologia, Servicio de Oncologia | Valencia | |
| United Kingdom | Department of Urological Research, Derriford Hospital | Devon | |
| United Kingdom | Clinical Research Centre, St George's Hospital, Urology Division | London | |
| United Kingdom | Department of Urology, St Bartholomew's Hospital | London | |
| United Kingdom | Imperial College School of Medicine, Dept Cancer Medicine | London | |
| United Kingdom | Department of Urology, East Surrey Hospital | Surrey | |
| United Kingdom | Royal Surrey County Hospital | Surrey | |
| United Kingdom | St Richard's Hospital | West Sussex | |
| United States | Alaska Clinical Research Center, LLC | Anchorage | Alaska |
| United States | Georgia Urology,PA Research Institute | Atlanta | Georgia |
| United States | University of Chicago, Section of Hematology/Oncology | Chicago | Illinois |
| United States | University of Illinois, Department of Urology | Chicago | Illinois |
| United States | Henry Ford Hospital | Detroit | Michigan |
| United States | Shands Hospital | Gainesville | Florida |
| United States | The Urologic Institute of New Orleans | Gretna | Louisiana |
| United States | Memphis Cancer Center | Memphis | Tennessee |
| United States | Sylvester Comprehensive Cancer Center | Miami | Florida |
| United States | San Bernardino Urological Associates | San Bernardino | California |
| United States | Virginia Mason Medical Center | Seattle | Washington |
| United States | Michiana Hematology/Oncology | South Bend | Indiana |
| United States | Washington University School of Medicine | St. Louis | Missouri |
| United States | Western Clinical Research, Inc. | Torrance | California |
| Lead Sponsor | Collaborator |
|---|---|
| Astellas Pharma Inc | Astellas Pharma US, Inc. |
United States, Australia, Belgium, France, Germany, Ireland, Netherlands, Poland, Spain, United Kingdom,
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04964271 -
Identification of Prostate Cancer Specific Markers in Patients Compared to Healthy Participants
|
||
| Completed |
NCT02546908 -
A Registry of Participants With Prostate Cancer in Asia
|
||
| Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
| Completed |
NCT01683994 -
Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT04838613 -
Study of Diagnostic Performance of [18F]CTT1057 in BCR
|
Phase 3 | |
| Completed |
NCT02364531 -
A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting
|
||
| Completed |
NCT01929655 -
Japanese BAY88-8223 Monotherapy Phase II Study
|
Phase 2 | |
| Active, not recruiting |
NCT05022849 -
A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants
|
Phase 1 | |
| Completed |
NCT03261999 -
Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer
|
Phase 3 | |
| Terminated |
NCT04907227 -
Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension
|
Phase 3 | |
| Active, not recruiting |
NCT03587285 -
A Pilot Study of Hormonal Therapy Combined With Central Memory T Cells (Tcm) for Patients With Advanced Prostate Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT02217566 -
Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy
|
Phase 2 | |
| Not yet recruiting |
NCT04101305 -
Measurement of Circulating Tumor Cells in Prostate Cancer
|
||
| Active, not recruiting |
NCT02950064 -
A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations
|
Phase 1 | |
| Terminated |
NCT03066154 -
Oral Docetaxel (ModraDoc/r) in Combination With Hormonal Treatment and Radiation Therapy in High-risk Prostate Cancer
|
Phase 1 | |
| Withdrawn |
NCT02905201 -
A Prospective Compliance Registry for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
|
N/A | |
| Completed |
NCT02692976 -
Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients
|
Phase 2 | |
| Terminated |
NCT01420965 -
Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer
|
Phase 2 | |
| Completed |
NCT01441713 -
Treatment Frequency and Satisfaction in Patients With Advanced Prostate Cancer
|
N/A |